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Abstract 
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from 
targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively 
registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. 
Logistic regression analysis was performed to identify risk factors for proven/probable IFD (PP-
IFD) during the early (days 0 to 40), late (days 41 to 100), and very late (days 101 to 365) phases 
after allo-HSCT and to evaluate the impact of PP-IFDs on 1-year overall survival. The cumulative 
incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12 months post-
transplantation. Multivariate analysis identified the following variables as associated with PP-IFDs: 
transplant from an unrelated volunteer donor or cord blood, active acute leukemia at the time of 
transplantation, and an IFD before transplantation in the early phase; transplant from an unrelated 
volunteer donor or cord blood and grade II-IV acute graft-versus-host disease (GVHD) in the late 
phase; and grade II-IV acute GVHD and extensive chronic GVHD in the very late phase. The risk 
for PP-IFD was significantly higher when acute GVHD was followed by chronic GVHD and when 
acute GVHD occurred in patients undergoing transplantation with grafts from other than matched 
related donors. The presence of PP-IFD was an independent factor in long-term survival (hazard 
ratio, 2.90; 95% confidence interval, 2.32 to 3.62; P < .0001). Our findings indicate that tailored 
prevention strategies may be useful in subpopulations at differing levels of risk for PP-IFDs. 
Introduction 
Invasive fungal diseases (IFDs), particularly invasive aspergillosis (IA), represent a leading cause of 
morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (allo-
HSCT) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14. Ongoing challenges are presented by the 
continuous evolution of the incidence, timing, and prognosis of IFDs owing to changes in transplant 
recipient populations and antifungal strategies. Therefore, ongoing epidemiologic investigation is 
advisable. 
Given the poor outcomes associated with IFDs in transplant recipients, there is much interest in 
identifying risk factors and prognostic factors that may help guide the development of tailored 
prevention strategies and more aggressive diagnostic and treatment approaches 2, 3, 8, 9, 10, 12, 
14 and 15. Although risk factors for IFDs have been evaluated extensively in allo-HSCT recipients, 
there are few studies describing specific variables related to outcome 1, 2, 8 and 9. 
To assess the current incidence, risk factors, and prognostic factors of IFDs in allo-HSCT patients, 
the Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data of patients 
undergoing allo-HSCT between 2008 and 2010. These data provide the basis for promoting direct 
efforts in risk stratification, prevention, and management of IFDs in allo-HSCT recipients. 
Methods 
The surveillance involved 30 transplantation centers in Italy for a period of 3 years from January 1, 
2008, to December 31, 2010. Study start time could differ among the centers, but all consecutive 
transplants were enrolled. Second and third allo-HSCTs were analyzed as a separate category when 
appropriate. 
Data collection for each case was interrupted at 12 months after transplantation, and thus the study 
end date was December 31, 2011. Data were entered into electronic case report forms, and all 
reported results are derived from the database frozen at June 30, 2012. The results of this study are 
reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) statement [16]. The study was approved by the Ethical Committee of each 
participating center, and informed consent was obtained from the patients. 
Data Collection 
Variables analyzed included patient characteristics, diagnosis and phase of the underlying disease; 
previous autologous HSCT (auto-HSCT) or allo-HSCT; proven, probable, or possible IFD 
documented within the 180 days before transplantation; cytomegalovirus (CMV) serology of donor 
and recipient; stem cell donor; stem cell source; pretransplantation conditioning regimen; the use of 
total body irradiation; the use of in vivo T cell depletion with antithymocyte globulin (ATG) or 
alemtuzumab; and the transplantation activity of the center (with the median number of patients 
enrolled [n = 48] used to stratify 15 centers with high transplantation activity and 15 centers with 
low activity). Post-transplantation data included primary and secondary antifungal prophylaxis 
during the engraftment phase and, in the event of graft-versus-host disease (GVHD), grade II-IV 
acute GVHD (aGVHD) and extensive chronic GVHD (cGVHD) diagnosed and staged according to 
standard criteria [17], CMV reactivation, remission status of underlying diseases, proven and 
probable IFDs (PP-IFDs), survival, and causes of death. Information pertaining to PP-IFDs included 
timing after allo-HSCT, microbiological data, and site of infection. 
Case Definitions 
Cases of PP-IFD were defined according to standard international criteria [18]. The clinical and 
laboratory data reported to define cases of PP-IFD were reviewed to determine the reliability of the 
diagnosis. Cases with IFD diagnosed before transplantation were analyzed as a separate category 
when appropriate. Onset of PP-IFD was defined as the day of the first positive radiologic exam, 
positive culture, or positive pathological test. PP-IFDs were classified as early (occurring ≤40 days 
after allo-HSCT), late (occurring 41 to 100 days after allo-HSCT), or very late (occurring 101 to 
365 days after allo-HSCT), consistent with previous analyses 9 and 10. The cutoff of 40 days for 
early PP-IFDs was chosen to ensure that the model reflected the engraftment period. The day 41 to 
day 100 interval for late PP-IFDs reflects the immediate postengraftment period, the risk of 
developing aGVHD, and early immunologic recovery. The cutoff of 101 to 365 days for very late 
PP-IFDs reflects the late or post-aGVHD period, the cGVHD period, and late immunologic 
recovery. 
Analyses 
The 12-month cumulative incidence of PP-IFDs was calculated accounting for the competing risks 
of infection-free death, retransplantation, and relapse of the underlying disease. The cumulative 
incidence of PP-IFDs was calculated for any type and status of the underlying disease; any type of 
stem cell donor, stem cell source, and pretransplant conditioning; history of IFD before 
transplantation; type of primary antifungal prophylaxis; aGVHD and cGVHD; and CMV 
infection/reactivation. Cumulative incidence was assessed using the cmprsk package in R version 
2.15 (R Project for Statistical Computing, Vienna, Austria). The associations among early, late and 
very late PP-IFDs and the foregoing risk factors were evaluated by landmark analysis. All factors 
were evaluated in multivariate models to control for potential confounders. Crude mortality rates at 
100 days after PP-IFD and at 12 months post-transplantation were calculated. Death was attributed 
to a PP-IFD in patients who failed to respond to therapy (ie, who had stable disease or disease 
progression) and in patients who demonstrated a partial response to therapy who died as the result 
of an acute event involving any of the sites of infection and in the absence of any other causes 
considered to have primarily contributed to death. 
Survival analyses were performed on the basis of the foregoing variables. The probability of 1-year 
survival from allo-HSCT was calculated using the Kaplan-Meier estimate, and the log-rank test was 
applied for univariate analyses. A 2-sided P value <.05 was considered to indicate statistical 
significance. Multivariate analyses were performed with the Cox proportional hazards regression 
model. The variables PP-IFD, aGVHD, cGVHD, and CMV infection/reactivation in the model were 
considered time-dependent covariates, with their effect evaluated only in the period after their 
onset. All significant variables in univariate analysis were included in multivariate analysis; final 
models were also evaluated with backward and stepwise functions. In all, 95% confidence intervals 
(CIs) are reported for the main summary statistics, and all statistical comparisons were based on 2-
tailed tests. Statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). All 
comparisons are 2-sided, with a nominal significance level of 5%. 
Results 
Patient Characteristics 
The 1858 allo-HSCTs analyzed in the study included 1771 first allo-HSCTs, 85 second allo-
HSCTs, and 2 third allo-HSCTs. Overall, 425 allo-HSCTs (22.9%) were preceded by an auto-
HSCT. The median number of transplants per center was 48.5 (range, 9 to 228). Demographic data 
and patient characteristics at the time of allo-HSCT are summarized in Table 1. 
 Antifungal Prophylaxis 
During the engraftment period, 92 patients who had experienced an IFD before transplantation 
(4.9%) received secondary antifungal prophylaxis, 1401 patients (75.4%) received primary 
antifungal prophylaxis with fluconazole only, 263 (14.1%) received primary antifungal prophylaxis 
with a mold-active drug, and 102 (5.5%) received no antifungal prophylaxis. Among the 641 
patients who experienced grade II-IV aGVHD and/or extensive cGVHD and did not receive 
antifungal therapy owing to a previous IFD, only 133 (20.7%) received mold-active primary 
antifungal prophylaxis. Considering that mold-active primary antifungal prophylaxis in patients 
with GVHD was given in a minority of patients and consisted of various drugs (liposomal 
amphotericin B, voriconazole, itraconazole, posaconazole, and caspofungin) administered alone or 
sequentially with heterogeneous start-and-stop timing after transplantation and frequently with 
intermittent administration, the variable “primary antifungal prophylaxis” administered after 
engraftment in patients with GVHD was not included in our risk analyses. In contrast, primary 
antifungal prophylaxis administered during the engraftment period was included in the variables 
considered for the PP-IFD risk analysis. 
Incidence of PP-IFDs 
Overall, in 164 of 1858 transplants (8.8%), a new PP-IFD or reactivation of a previous IFD was 
documented before the presence of any competing risk. IA was the most common infection (133 
cases; 81.1%), followed by invasive candidiasis (18 cases, 11·0%), zygomycosis (6 cases, 3.7%), 
fusariosis (3 cases, 1.8%), and infections by other fungi (Scedosporium sp, Scopulariopsis sp, 
Cryptococcus neoformans, and Geotrichum capitatum, 1 case each). 
The cumulative incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 
12 months from transplantation (Figure 1). One competing risk was present in 769 cases (41.4%). 
The rate of PP-IFDs at the transplantation centers ranged from 0% to 23.1% (Figure 2). The 12-
month cumulative incidence of PP-IFD was 9.9% in the 15 centers with the highest transplantation 
activity and 5.7% in the 15 centers with the lowest activity (P = .004). The cumulative incidence of 
PP-IFDs according to demographics, underlying disease, and transplantation variables is presented 
in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Risk Factors for PP-IFD in the Early, Late, and Very Late Phases after Allo-HSCT 
The 164 cases of PP-IFD included 94 (57.3%) early, 39 (23.8%) late, and 31 (18.9%) very late 
cases. The early phase had the highest rate of IFD irrespective of fungal pathogen (Figure 3). In a 
landmark analysis, the cumulative incidence of PP-IFDs was 5,1% in the early phase, 1.9% in the 
late phase, and 2.9% in the very late phase. Risk factors for PP-IFD during each phase after allo-
HSCT are shown in Table 3. 
 
 
  
  
Risk of PP-IFD in Patients with aGVHD or cGVHD 
After excluding 20 patients who developed a PP-IFD before the occurrence of GVHD, 641 patients 
who experienced grade II-IV aGVHD and/or extensive cGVHD were included in this analysis. A 
PP-IFD was documented in 28 of 388 patients (7.2%) with aGVHD not followed by cGVHD, in 25 
of 129 patients (19.4%) with aGVHD followed by cGVHD, and in 4 of 124 patients (3.2%) with 
cGVHD not preceded by aGVHD (ie, “de novo” cGVHD). The median interval from the onset of 
GVHD to detection of IFD was 38 days for patients with aGVHD not followed by cGVHD, 80 days 
for patients with aGVHD followed by cGVHD, and 25.5 days for patients with cGVHD not 
preceded by aGVHD (Figure 4). 
 
 
 
 
The cumulative incidence of PP-IFD, starting from GVHD onset, is shown in Figure 5 according to GVHD 
group and donor type. In patients with aGVHD not followed by cGVHD, the cumulative incidence of PP-IFD 
was 2.3% in recipients of allo-HSCT from a matched related donor (MRD) and 10% in recipients of allo-HSCT 
from an alternative donor (mismatched related donor [MMRD], UD, or CB) (P = .0039). In allo-HSCT 
recipients with aGVHD followed by cGVHD, the cumulative incidence of PP-IFD was 10% in recipients of an 
MRD graft and 25.3% in recipients of a graft from an alternative donor (P = .06). In patients with de novo 
cGVHD, the cumulative incidence of PP-IFD was 3% for the former group 3.5% for latter (P = .90). The 
cumulative incidence of PP-IFDs at 6 months after onset of GVHD was 7.1% in 334 patients with a grade II 
aGVHD and 12.3% in 178 patients with grade III-IV aGVHD (P = .049). 
 
  
Survival 
The mortality rate at 100 days from the diagnosis of PP-IFD was 46.3% (76 of 164 patients). In 
patients with IA, invasive candidiasis, and non-Aspergillus–non-Candida infections, it accounted 
for 48.5%, 39%, and 75%, respectively. Among the 76 patients who died within 100 days from the 
diagnosis of a PP-IFD, the infection was considered the primary cause of death in 34 (44.7%), with 
an attributable mortality rate of 20.7%. The probability of survival to 6 months after diagnosis of 
PP-IFD was roughly 55% in patients in the early, late and very late phases after receipt of allo-
HSCT ( Figure 6). 
  
The overall survival of the entire population at 1 year after allo-HSCT was 64.4% (95% CI, 62.2% to 66.6%). 
Multivariate analysis identified older age, active acute leukemia at transplantation, IFD in the 180 days 
before transplantation, receipt of a CB transplant, receipt of a UD transplant, aGVHD, and PP-IFD (hazard 
ratio [HR], 2.90; 95% CI, 2.32 to 3.62; P < .0001) as independent survival factors ( Table 5). 
 
  
 
Discussion 
Few large, prospective surveillance studies on IFDs in allo-HSCT recipients have been published to 
date 12 and 13. A study from the sentinel surveillance system of the Transplant-Associated 
Infections Surveillance Network (TRANSNET) evaluated the incidence and burden of IFDs in 6666 
allogeneic HSCTs performed between March 2001 and March 2006 in 23 transplantation centers 
(representing approximately 20% of HSCT recipients in the United States during the study period) 
with the aim of estimating the cumulative incidence of PP-IFDs and collecting clinical, diagnostic, 
and outcome information for each reported infection [12]. A study by the Prospective Antifungal 
Therapy (PATH) Alliance registry collected data and monitored trends in epidemiologic 
characteristics, diagnosis, treatment, and outcomes of 234 allo-HSCT recipients with PP-IFD 
observed in 23 centers in the United States and Canada between July 2004 and September 2007 
[13]. 
The present GITMO survey, which includes approximately 40% of allo-HSCTs performed in Italy 
during the years 2008 to 2010, was a prospective study designed to critically assess not only the 
incidence, but also the risk factors for and prognostic role of PP-IFDs at 1 year from allo-HSCT. A 
valuable characteristic of this study is the availability of complete denominator data collected 
prospectively for consecutive allo-HSCT recipients at each center. 
The overall 12-month cumulative incidence of PP-IFDs was 8.8%. Of these PP-IFDs, 81% were 
caused by IA and 11% were caused by Candida species, with other infections relatively uncommon. 
The incidence of PP-IFDs by allo-HSCT graft source was 4.6% for MRD, 8.2% for MMRD, 11.8% 
for UD, and 17.3% for CB. These results are comparable in some respects to those reported in the 
TRANSNET survey, with 12-month cumulative incidences of 5.8% for MRD, 8.1% for MMRD, 
and 7.7% for UD (with specific data for the few CB transplants not reported) [12]. The incidence of 
PP-IFDs among centers ranged from 0% to 23%, with the highest incidences in the larger centers. A 
potential center effect may represent a limit of our survey and of any multicenter trial. To evaluate 
the potential role of the different clinical care habits, we stratified the centers according to 
transplantation activity, which may reflect the different types of transplants and care capabilities. 
Multivariate analysis did not identify transplantation activity as an independent risk factor, although 
it was borderline significant in the early phase after allo-HSCT. The site-specific variation in the 
incidence of PP-IFDs may reflect differences in patient populations, transplantation programs, and 
diagnostic accuracy, particularly for mold infections. 
The timing of PP-IFDs in our study was rather unexpected: indeed, early infections represented 
57.3% of all infections documented during the first year after allo-HSCT. This result contrasts with 
previous studies in which the vast majority of cases were documented after the engraftment period 
8 and 12. Several factors may explain the high incidence of PP-IFDs during the early 
transplantation phase in our series. Transplant with a UD or CB graft, active acute leukemia at the 
time of transplantation, and an IFD before transplantation were found to be independent factors for 
the development of an early PP-IFD. One or more of these conditions were present in more than 
one-half of the patients in our study, in line with the increasing use of transplants from alternative 
donors and a trend toward less-restrictive eligibility criteria worldwide. The high risk for early IFDs 
in patients who receive a transplant from an alternative donor, particularly CB, or in those with a 
history of infection before transplantation is well known 5, 6, 7, 10 and 19; however, the high rate 
of early PP-IFDs in patients with active acute leukemia at the time of transplantation is an original 
finding. The severe immunologic impairment associated with active disease, multiple intensive 
chemotherapy treatments, and late engraftment frequently seen in these patients may justify the high 
early post-transplantation risk of PP-IFD 20, 21 and 22. 
GVHD represents a known risk factor for IFD, and mold-active primary antifungal prophylaxis is 
recommended in patients with GVHD while receiving initiation of immunosuppressive therapy 2, 
23 and 24. Our study confirms that aGVHD and cGVHD are independent risk factors for the 
development of late and very late PP-IFDs. The subanalysis of patient populations with different 
types and severity of GVHD and different donors revealed a significantly different risk profile, 
however. The cumulative incidence of PP-IFDs was high in patients with aGVHD developing after 
transplantation from an alternative donor, and was even higher when aGVHD was followed by 
cGVHD regardless of donor type, up to 25% in recipients of an alternative donor graft. Of interest, 
the cumulative incidence of PP-IFDs was relatively low (<4%) in patients with de novo cGVHD 
regardless of donor type. As expected, the risk for PP-IFD was significantly higher in patients with 
grade III-IV aGVHD compared with those with grade II aGVHD [2]. 
In this study, we were not able to evaluate the impact of mold-active primary antifungal prophylaxis 
on the epidemiology of post-transplantation PP-IFDs either during the engraftment period or in the 
event of GVHD, likely related to the wide variability in prophylaxis according to clinical indication, 
type of antifungal drug, and timing and duration of administration. The real life data from our study 
demonstrate the difficulty of applying the guidelines for antifungal prophylaxis in the various 
clinical settings of allo-HSCT, and suggest the need for risk- and time-adapted indications 
14 and 24. 
Reported mortality rates in allo-HSCT recipients with IFD have been as high as 80% 1, 13 and 25; 
however, more recent data seem to show improving outcomes, particularly for IA, possibly related 
to the extensive use of voriconazole 8, 15 and 26. In the PATH Alliance study, the overall mortality 
rate at 12 weeks after documented IA was 35.5% [13], compared with the 48.5% rate in our study. 
Of interest, mortality attributed to PP-IFD was 20.7%, confirming the improvement in therapeutic 
approaches to these infections with favorable impacts on short-term outcome. 
Whereas in previous studies, outcomes of IFDs were usually evaluated at 3 months after 
transplantation, we chose to evaluate outcomes at 1 year. In our study, in addition to the well-
known factors predicting poor outcome, including older age, active acute leukemia at 
transplantation, IFD before transplantation, alternative donor graft, and aGVHD, PP-IFDs represent 
an independent prognostic factor for survival. This finding suggests that although PP-IFDs may be 
cured or controlled in most cases, they are of poor prognostic significance, likely because of the 
underlying condition that favored the development of the infection, and also because of the possible 
interference of IFD with the management of other post-transplantation complications, such as 
GVHD, viral infection, and hematologic relapse. 
In conclusion, our study has identified important risk factors for PP-IFD during the preengraftment 
and postengraftment phases in a real life allo-HSCT scenario. The demonstration of an independent 
impact of these complications on transplantation outcomes suggests the need for changes in 
supportive care strategies to decrease the burden of IFD in allo-HSCT recipients. Of relevance, our 
experience shows an absence of consensus in the practice of antifungal prophylaxis in the allo-
HSCT community, likely related to the lack of specific epidemiologic information. Our present 
findings may be useful in identifying the subpopulations of allograft recipients who might benefit 
from targeted prevention strategies. 
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